Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

June 2017 Scleroderma News

Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial. Cytori Therapeutics, Inc. today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subject’s 48 week visit was conducted earlier this week. Globe Newswire, 05/23/2017. (Also see Scleroderma Clinical Trials)

The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. The analysis revealed that gene variation in four genes – IRF5, STAT4, CTGF and IRAK1 – was linked to lung fibrosis in scleroderma. PubMed, Rheumatol Int, 04/22/2017. (Also see Pulmonary Fibrosis)

Systemic sclerosis (SSc) is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. These findings suggest that gastrointestinal tract dysbiosis may be a pathological feature of the SSc disease state. BMJ Open Gastro, 2017; 4:e000134. (Also see Bowel Dysfunction)

Quantitative Assessment of Skin Stiffness in Localized Scleroderma (LS) Using Ultrasound Shear–Wave Elastography. This non–invasive, real–time imaging technique is an ideal tool for assessing and monitoring LS disease severity and progression. PubMed, Ultrasound Med Biol, 04/27/2017. (Also see Localized Scleroderma and Skin Fibrosis)

Pulmonary Artery (PA) Dimensions as a Prognosticator of Transplant–Free Survival in Scleroderma Interstitial Lung Disease (SSc–ILD). In SSc–ILD patients, a PA:ascending aorta (Ao) ratio ≥1.1 is associated with higher risk of lung transplant or death. PubMed, Lung, 04/29/2017. (Also see Pulmonary Fibrosis)

Unifying mechanism for different fibrotic diseases. Here, we demonstrate that many endstage fibrotic diseases converge in the activation of the Activator protein 1 transcription factor c-JUN in the pathologic fibroblasts. PubMed, Proc Natl Acad Sci U S A, 2017 May 2;114(18):4757-4762. (Also see Fibroblasts)

Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis–associated Pulmonary Arterial Hypertension (SSc–PAH) and Idiopathic Pulmonary Arterial Hypertension (IPAH). In patients with SSc–PAH, echocardiographic RV function does not improve over time compared with that of patients with IPAH, despite institution of pulmonary artery vasodilator therapies. PubMed, Ann Am Thorac Soc, 2017 May;14(5):682-689. (Also see Pulmonary Hypertension)

Cell Therapy for Localized Scleroderma Can Reverse Fibrosis in Mice. A cell therapy based on injected genetically modified human skin cells and a pill that activates a protein has the capacity for breaking down fibrosis in localized scleroderma – at least in mice. Scleroderma News, 05/11/2017. (Also see Skin Fibrosis)

The Gastrointestinal dysmotility and infections in Systemic Sclerosis – A real world scenario. Motility abnormalities in the esophagus make them prone for super added infections and should be investigated for early detection and treatment. PubMed, Curr Rheumatol Rev, 04/25/2017. (Also see Dysmotility Syndrome)

Expanded Access Programs. A Expanded Access Program (EAP) allows physicians and patients access to much needed medicines when there are no other viable options left. These may be investigational therapies as well as drugs not available in the patients' country and the ultimate intention is to treat unmet clinical need. WEP Clinical. (Also see Clinical Trials and Medication Programs)

Go to Scleroderma Medical News: May 2017

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.